Heidelberg Pharma to host R&D Webinar following novel data presented at AACR

Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST/15.00 BST, for investors, analysts and media.

The R&D webinar will feature presentations from Heidelberg Pharma’s management team, alongside leading Key Opinion Leaders (KOLs) in the ADC field, Rakesh Dixit, PhD, CEO of Bionavigen, Gaithersburg, USA, and Jonathan Kaufman, MD, Associate Professor of Hematology & Medical Oncology, Emory University School of Medicine, Atlanta, USA.

Read more…